Patients that require reconstruction of large sections of bone and skin currently have limited options. With its 3M3 platform, Novadip Biosciences hopes to change patient lives by offering new regenerative medicine treatment options for patients with a range of conditions, including large bone defects, bone non-union, and spine fusion. In this Q&A, Novadip’s co-founder and Chief Executive Officer Denis Dufrane, M.D., Ph.D., discusses the company’s autologous cell-based and off-the-shelf cell-free products that are advancing through and to the clinic, with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D.
